Patent · US Active

Use of pemirolast in the treatment of acute asthma

US9492454B2 · kind B2 · utility

0Cited by

1References

8Claims

0Family size

Assignee

RSPR Pharma AB · SE

Inventors

Johan Raud · Stockholm, SE
Carl-Johan Dalsgaard · Stockholm, SE
Jesper SÄFHOLM · Stockholm, SE

Key dates

Filing date	Feb 4, 2016
Grant date	Nov 15, 2016
Priority date	—
Expiry date	Feb 4, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P11/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

According to the invention there is provided pemirolast, or a pharmaceutically acceptable salt thereof, for use in the therapeutic treatment of asthma, such as an acute asthma attack. Suitable lower doses of pemirolast are least about 110 mg per day.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.